

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/583,839
				Filing Date	March 8, 2007
				First Named Inventor	Boatman, P. Douglas
				Art Unit	1645
				Examiner Name	
(Use as many sheets as necessary)					
Sheet	1	of	3	Attorney Docket Number	
				AREN-073	

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials'	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		WO 01/12630 A1	02-22-2001	SEPRACOR INC.		
		WO 02/16432 A2	02-28-2002	NOVO NORDISK		
		WO 03/039434 A2	05-15-2003	UNIVERSIDADE FEDERAL DE MINAS GERAIS UFMG		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
Sheet	2	of	3	Application Number	10/583,839
				Filing Date	March 8, 2007
				First Named Inventor	Boatman, P. Douglas
				Art Unit	1645
				Examiner Name	
				Attorney Docket Number	AREN-073

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
		AMBROZ, C., et al. The mas oncogene enhances angiotensin-Induced [Ca2+]i responses in cells with pre-existing angiotensin II receptors. <i>Biochim Biophys Acta</i> . 1991, vol. 1133, no. 1, pp. 107-11.			
		CASTRO, C., et al. Effects of genetic deletion of angiotensin-(1-7) receptor Mas on cardiac function during Ischemia/reperfusion in the isolated perfused mouse heart. <i>Life Sciences</i> . 2006, vol. 80, pp. 264-268.			
		COSSY, J., et al. Regioselective ring opening of epoxides by nucleophiles mediated by lithium bis(trifluoromethanesulfonimide). <i>Tetrahedron Letters</i> . 2002, vol. 43, pp. 7083-7086.			
		DONG, X., et al. A diverse family of GPCRs expressed in specific subsets of nociceptive sensory neurons. <i>Cell</i> . 2001, vol. 106, pp. 619-32.			
		FERREIRA, A. J., et al. Angiotensin-(1-7) improves the post-ischemic function in isolated perfused rat hearts. <i>Brazilian Journal of Medical and Biological Research</i> . 2002, vol. 35, pp. 1083-90.			
		JACKSON, T. R., et al. The mas oncogene encodes an angiotensin receptor. <i>Nature</i> . 1988, vol. 335, pp. 437-40.			
		LEE, S., et al. Improved catalysts for the palladium-catalyzed synthesis of oxindoles by amide α -arylation. Rate acceleration, use of aryl chloride substrates, and a new carbene ligand for asymmetric transformations. <i>J Org Chem</i> . 2001, vol. 66, pp. 3402-3415.			
		ONG, H., et al. Novel tetracyclic spiroperidolines. 3. 1-Arylspiro[indoline-3,4'-peperidine]s as potential antidepressants. <i>J Med Chem</i> . 1983, vol. 26, pp. 981-986			
		SANTOS, R., et al. Angiotensin-(1-7): an update. <i>Regulatory Peptides</i> . 2000, vol. 91, pp. 45-62.			
		SANTOS, R., et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. <i>PNAS</i> . 2003, vol. 100, no. 14, pp. 8258-8263.			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS: SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
				Application Number	10/583,839
				Filing Date	March 8, 2007
				First Named Inventor	Boatman, P. Douglas
				Art Unit	1645
				Examiner Name	
Sheet	3	of	3	Attorney Docket Number	AREN-073

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		VON BOHLEN UND HALBACH, O., et al. Interaction between Mas and the angiotensin AT1 receptor in the Amygdala. J Neurophysiol. 2000, vol. 83, pp. 2012-2021.			
		YOUNG, D., et al. Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains. Cell. 1986, vol 45, pp. 711-719.			
		Results from Chemical Search conducted on May 13, 2005 (05-13-2005).			
		DATABASE CHEMCATS; Chemical Abstracts Service; Columbus, Ohio, USA; 1 January 2004 (01-01-2004) XP-002335475. Order Numbers: 0094_12313-11057-104, 0094_12313-11049-104, 0094_12313-14176-104, 0094_12313-11036-104, 0094_12313-11025-104, 0094_12823-10302-104, 0094_12823-12850-104, 0094_12823-10292-104, 0094_12823-10137-104, 0094_12823-10655-104, 0094_12823-10290-104, 0094_12823-11049-104, 0094_12823-18427-104, 0094_12823-10654-104, 0094_12823-10343-104, 0094_12823-12783-104, 0094_12823-12466-104, 0094_12823-10295-104, 0094_12823-12851-104, 0094_12823-11048-104, 0094_12823-14325-104, 0094_12823-13354-104, 0094_12823-11057-104, 0094_12823-12663-104, 0094_12823-13988-104, 0094_12823-10309-104, 0094_12493-10292-103, 0094_12493-10295-103, 0094_12493-10300-103, 0094_12493-10302-103, 0094_12493-10309-103, 0094_12493-10343-103, 0094_12493-10290-104, 0094_12493-10292-104, 0094_12493-10295-104, 0094_12493-10300-104, 0094_12493-10302-104, 0094_12493-10309-104, 0094_12493-10343-104, 0094_12313-11048-104, 0094_12313-11019-104, 0094_12313-13988-104, 0094_12313-13354-104, 0094_12313-12783-104, 0094_12313-12663-104, 0094_12313-12466-104, 0094_12313-12257-104, 0094_12313-10912-104, 0094_12313-10655-104, 0094_12493-10654-104, 0094_12493-10550-104			
		DATABASE ZREGISTRY ONLINE; 16 AUGUST 2002 (2002-08-16), XP-002340778, Database accession no. RN: 444054-63-1.			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.